Business Wire

$300 Billion in Life Sciences Revenue at Risk. The Intelligence Behind It Is Months Old. Behavior Labs Launches a Decision Intelligence Platform That Addresses This Gap.

9.4.2026 15:00:00 CEST | Business Wire | Press Release

Share

Behavior Labs, a new life sciences intelligence company, today launched a platform that gives pharmaceutical and medical device teams continuous strategic intelligence — powered by what the company calls a World Model, a continuously operating model of the market reality each product exists in. The platform replaces quarterly review cycles with daily, cross-validated insight across the full product lifecycle, from patent cliff defence and biosimilar war-gaming to regulatory pathway optimisation and post-market surveillance.

Behavior Labs delivers intelligence from day zero using public, regulatory, and commercial data sources, then compounds in value as teams layer in their own strategic context — all within a secure, isolated environment where client data is never used to train models or shared across tenants.

The Problem: The Ground Truth Gap

In most life sciences organisations, the gap between what leadership decides in a boardroom and what is actually happening in the field — the “ground truth” gap — costs months of wasted effort and billions in misaligned execution. Medical affairs generates evidence that commercial teams can’t access. Pricing models don’t reflect competitive signals or emerging policy shifts like the Inflation Reduction Act’s Medicare price negotiations. In devices, regulatory teams choose submission pathways without real-time competitive intelligence, and post-market surveillance teams review complaints quarterly while safety signals emerge weekly. By the time teams align, the landscape has shifted. Behavior Labs eliminates that lag.

What Teams Get

The platform delivers continuous intelligence across the decisions life sciences teams make every week: competitive monitoring of filings, hiring patterns, patent activity, and publication signals with recommended actions routed to the team that needs to respond. Market access and pricing intelligence including formulary defence, net price modelling, and HEOR evidence synthesis. Medical affairs support with evidence gap analysis, KOL landscape monitoring, and medical-commercial messaging alignment. And for products approaching loss of exclusivity, scenario modelling that war-games biosimilar entry dynamics and franchise defence strategies across the full lifecycle.

For medical device companies, the platform adds regulatory pathway optimisation across 190,000+ FDA device clearances including 510(k), De Novo, and PMA records; continuous post-market surveillance with MAUDE signal detection and complaint narrative analysis; hospital market access intelligence including Value Analysis Committee and GPO tracking; and portfolio lifecycle analytics for companies managing tens of thousands of SKUs.

”What used to take a team months to compile — competitive landscapes, evidence gaps, pricing scenarios — the platform produces continuously and keeps current. That’s the shift: from quarterly snapshots to daily intelligence,” said Nicholas King, Founder & CEO. “And the platform compounds its knowledge with every interaction — it doesn’t forget context between meetings, and it doesn’t walk out the door when an employee leaves.”

How It Works

Unlike enterprise AI tools that require months of data integration, Behavior Labs starts delivering intelligence from day zero. The platform is built around a World Model — a living intelligence layer that integrates public and commercial data sources — ClinicalTrials.gov, FDA and EMA regulatory filings, patent databases, published literature, payer formulary data, congress abstracts, the 510(k)/PMA/De Novo clearance databases, and MAUDE adverse event reports — cross-validated into unified product profiles. Each client works within a secure, isolated tenant where they layer in their own competitive priorities, decision processes, and first-party data. The result is not a replacement for a team’s expertise — it’s an acceleration of it.

Availability

Behavior Labs is available immediately. For teams evaluating the platform, Behavior Labs offers a single-product intelligence assessment — a focused analysis of one at-risk or high-priority asset — with no platform commitment required. Full lifecycle coverage spans 12 pharmaceutical stages and 12 medical device stages.

To schedule a briefing or request an assessment, visit behaviorlabs.ai or contact info@behaviorlabs.ai.

About Behavior Labs

Behavior Labs is a decision intelligence company purpose-built for the global life sciences industry. Its platform — built around a continuously operating World Model — combines broad public, regulatory, and commercial evidence with each client’s own strategic context to deliver continuous competitive intelligence, scenario modelling, and evidence synthesis across pharmaceutical and medical device lifecycles. Behavior Labs never trains on client data. The company is a subsidiary of Data Kinetic Corp and is headquartered in Austin, Texas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409090144/en/

Contacts

Brook Miller +1 (737) 520-3755 | brook@datakinetic.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CORRECTING and REPLACING Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 18:10:00 CET | Press Release

Please replace the release issued Nov. 12, 2026, at 11:00 p.m. PT/Nov. 13, 2026, at 2:00 a.m. ET with the following corrected version due to multiple revisions in the third paragraph. This release has been updated to ensure the accuracy of certain references in the original version. The updated release reads: YAMAHA TO ACQUIRE DISGUISE, EXPANDING ITS CAPABILITIES IN INTEGRATED AUDIO, VIDEO, LIGHTING AND MEDIA Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into soft

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press Release

VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware of the promotion and sale of vehicles that it believes were produced in violation of its intellectual property rights. White s.r.o. therefore decided to take direct action in China, entrusting the protection of its rights to Shanghai-based

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press Release

LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and CEO of LangChain. "Every company should be free to choose the best models for its needs, control its data a

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press Release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurrent platform is the right foundation for that. Operational orchestration builds on it by connecting planning, decisions and ex

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press Release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medical was $16 million, up 22% year-over-year. Net income margin was 27%, a decrease of 3 percentage points year-over-year. Adjusted EBITDA1 was $28 million, up 66% year-over-year. Adjusted EBITDA margin1 expanded 9 percentage points year-over-year to 47%. Basic earnings per share (EPS) was $0.15, u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye